Alkem’s Mandva API Plant Clears USFDA Audit With Zero 483s
Alkem Laboratories’ Mandva API facility cleared a five-day USFDA inspection (26–30 October 2026) with no Form 483 observations, a cleaner result than the site’s 2023 audit.
ALKEM-LABORATORIES
Alkem Laboratories Unveils MediSamvad: A Digital Knowledge Platform for Healthcare Professionals
Alkem Laboratories Ltd. has launched MediSamvad, a pioneering digital platform designed to equip healthcare professionals (HCPs) with the latest global […]
Alkem Laboratories Partners with Takeda to Launch Vonoprazan for Gastroesophageal Reflux Disease in India
Alkem Laboratories Ltd. (BSE: 539523, NSE: ALKEM), a prominent Indian pharmaceutical company has announced a strategic non-exclusive patent licensing agreement […]
Alkem Laboratories Intensifies ‘Reliever Free India’ Initiative on World Asthma Day 2024
In commemoration of World Asthma Day, 7th May 2024, Alkem Laboratories has unveiled an ambitious expansion of its groundbreaking ‘Reliever […]
